Mesoblast Limited

ASX:MSB ISIN:AU000000MSB8

 Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.

Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.

The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.

Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients. 
 
     

View in Other Languages

News

Mesoblast Limited (ASX:MSB) Clear To Proceed With Angioblast Acquisition

🕔11/19/2010 2:47:27 PM 3123

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the required period for any antitrust objection under the United States Hart-Scott-Rodino(HSR) anti-trust improvement Act 1976 in respect of its acquisition of Angioblast Systems Inc. has expired.

Read Full Article

Mesoblast Limited (ASX:MSB) Announce Positive Results Of Novel Heart Attack Treatment Presented At Premier USA Cardiology Conference

🕔11/16/2010 10:06:38 AM 2994

Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) announced that positive preclinical trial results were today presented at the American Heart Association's annual conference in Chicago showing that the company's proprietary allogeneic stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.

Read Full Article

Mesoblast Limited (ASX:MSB) Awarded U.S. Government Grants For Further Development of Adult Stem Cell Products

🕔11/8/2010 10:18:56 AM 3158

Regenerative medicine company, Mesoblast Limited (ASX:MSB) (USOTC:MBLTY), today announced that its United States associate company, Angioblast Systems, has been awarded $1.2 million in grants under the United States Government's Qualifying Therapeutic Discovery Project (QTDP) program.

Read Full Article

Mesoblast Limited (ASX:MSB) Presented Positive Results From Phase 2 Lumbar Fusion Trial At International Investor Conference

🕔10/21/2010 10:21:45 AM 4666

Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that interim results from its Phase 2 clinical trial for minimally invasive posterior lumbar spinal fusion showed that its proprietary "off-the-shelf" product NeoFuse (TM) was both safe and effective.

Read Full Article

Mesoblast Limited (ASX:MSB) Acquisition Of Angioblast Systems Inc. By Angioblast Stockholders

🕔10/20/2010 10:46:28 AM 3313

Stockholders of United States adult stem cell company Angioblast Systems Inc. voted unanimously at a special stockholders' meeting held 19 October in favour of becoming a wholly-owned subsidiary of publicly listed global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY).

Read Full Article

Mesoblast Limited (ASX:MSB) Targets Broader Cancer Indications For Bone Marrow Transplant Product

🕔10/14/2010 9:41:54 AM 2833

Australian regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it is broadening the oncology applications of its "off-the-shelf" cell product for expansion of haematopoietic stem cells in patients with blood cancers.

Read Full Article

Acquisition Of US Company Ratified By Mesoblast Limited (ASX:MSB) Shareholders

🕔9/22/2010 6:07:17 PM 2723

Shareholders of Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today overwhelmingly approved the acquisition of its United States associate company, Angioblast Systems Inc.

Read Full Article

Speech By Mesoblast Limited (ASX:MSB) Chairman Brian Jamieson To Extraordinary General Meeting

🕔9/22/2010 2:38:24 PM 3215

Mesoblast Limited (ASX:MSB) (PINK:MBLTY) is pleased to release its Chairman Brian Jamieson's speech at the Extraordinary General Meeting.

Read Full Article

Mesoblast Limited (ASX:MSB) Featured Prominently At International Scientific Conferences

🕔9/20/2010 9:28:25 AM 3145

Clinical advances by regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) were featured prominently at the 39th annual meeting of the International Society for Experimental Hematology (ISEH) and the Tissue Engineering and Regenerative Medicine International Society (TERMIS) Asia Pacific meeting, both held over the past several days.

Read Full Article

Mesoblast Limited (ASX:MSB) Financial Year End Results: Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

🕔8/26/2010 10:22:26 AM 4241

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today reported its results for the year ended 30 June 2010.

Read Full Article
###

221,475 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 293) (Last 30 Days: 1166) (Since Published: 74600) 

Company Data

    Headquarters
  • Level 39
    55 Collins Street
    Melbourne 3000
    AUSTRALIA
  • Telephone
  • +61-3-9639-6036 
  • Fax
  • +61-3-9369-6030 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2004/12/16 
  • Homepage
  • www.mesoblast.com

More News Results

  • 2024/11/21: Becoming a substantial holder*
  • 2024/11/15: Results of Meeting*
  • 2024/11/15: Final Director's Interest Notice*
  • 2024/11/15: CEO Presentation to 2024 Annual General Meeting*
  • 2024/11/15: Mesoblast Chair Message to 2024 AGM*
  • 2024/11/14: Response to ASX Price Query*
  • 2024/11/12: Notification regarding unquoted securities - MSB*
  • 2024/11/07: Warrant Prospectus Related to Convertible Note Agreement*
  • 2024/11/05: Ceasing to be a substantial holder*
  • 2024/10/31: Quarterly Activities/Appendix 4C Cash Flow Report*
*refer to company website

Presentations

Download Presentation